Sacituzumab Govitecan (SG) Clinical Trials

8 actively recruiting trials across 5 locations

Also known as: GS-0132, IMMU 132, IMMU-132, Sacituzumab Govitecan-hziy, Trodelvy +1 more

Pipeline

Phase 2: 1Phase 3: 1Phase 1/2: 3Phase 2/3: 1

Top Sponsors

Peking University Cancer Hospital & Institute2
Yale University1
University of California, Irvine1
University Hospital Heidelberg1
Marengo Therapeutics, Inc.1

Indications

Cancer8
Breast Cancer4
Trop21
Brain Metastases From Breast Cancer1
Triple Negative Locally Advanced Non-resectable Breast Cancer1

Other3 trials

Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study

Sacituzumab Govitecan in Metastatic Colorectal Cancer

Phase 2/3

Trop-2 Targeted PET Probes in Advanced TNBC

N/A

Anaheim, California1 trial

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

Los Angeles Cancer Network

Phase 3

Los Angeles, California1 trial

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

USC Norris Comprehensive Cancer Center

Phase 1/2

Orange, California1 trial

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence

Chao Family Comprehensive Cancer Center, University of California, Irvine

Phase 2

New Haven, Connecticut1 trial

Saci Nivo Rela for TNBC

Yale University

Phase 1/2

Boston, Massachusetts1 trial

Sacituzumab Govitecan Plus EV in Metastatic UC

Dana Farber Cancer Institute

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.